Suzhou Zelgen Biopharmaceuticals Co., Ltd. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 98.58 million compared to CNY 27.98 million a year ago. Revenue was CNY 98.58 million compared to CNY 27.98 million a year ago. Net loss was CNY 292.67 million compared to CNY 228.37 million a year ago. Basic loss per share from continuing operations was CNY 1.22 compared to CNY 0.98 a year ago. Diluted loss per share from continuing operations was CNY 1.22 compared to CNY 0.98 a year ago.